Cerus Corporation to Participate at the Cowen 42nd Annual Health Care Conference

Rhea-AI Summary

Cerus Corporation (NASDAQ: CERS) announced that CFO Kevin D. Green will participate in the Cowen 42nd Annual Health Care Conference on March 9, 2022, at 1:30 p.m. EST. A live webcast will be accessible on the company's Investor Relations page, with a replay available for two weeks post-event. Cerus focuses on ensuring the safety of the global blood supply with products like the INTERCEPT Blood System, which is FDA-approved for platelets and plasma and under review for red blood cells in Europe. More details can be found on their website.

CONCORD, Calif.--(BUSINESS WIRE)-- Cerus Corporation (Nasdaq: CERS) today announced that Kevin D. Green, Cerus’ chief financial officer, is scheduled to participate at the Cowen 42^nd Annual Health Care Conference on Wednesday, March 9, 2022 at 1:30 p.m. EST.

A live webcast of the event will be available on the Investor Relations page of the Cerus web site at http://www.cerus.com/ir. A replay will be available for approximately two weeks following the completion of the event.

ABOUT CERUS

Cerus Corporation is dedicated solely to safeguarding the world’s blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE Mark and FDA approval for these two blood components. The INTERCEPT red blood cell system is under regulatory review in Europe, and in late-stage clinical development in the US. Also in the US, the INTERCEPT Blood System for Cryoprecipitation is approved for the production of INTERCEPT Fibrinogen Complex, a therapeutic product for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. For more information about Cerus, visit www.cerus.com and follow us on LinkedIn.

INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220225005023/en/

Matt Notarianni – Senior Director, Investor Relations

Cerus Corporation

925-288-6137

Source: Cerus Corporation

FAQ

When is Kevin D. Green speaking at the Cowen 42nd Annual Health Care Conference?

Kevin D. Green will speak on March 9, 2022, at 1:30 p.m. EST.

Where can I watch the webcast of the Cowen 42nd Annual Health Care Conference featuring Cerus?

The live webcast can be viewed on Cerus Corporation's Investor Relations page at www.cerus.com/ir.

What is the INTERCEPT Blood System developed by Cerus Corporation?

The INTERCEPT Blood System is a pathogen reduction technology for blood components, approved for platelets and plasma.

Is Cerus Corporation's INTERCEPT red blood cell system approved?

No, the INTERCEPT red blood cell system is currently under regulatory review in Europe and in late-stage clinical development in the U.S.

What specific products does Cerus manufacture for blood safety?

Cerus manufactures the INTERCEPT Blood System for platelets, plasma, and has a system for producing INTERCEPT Fibrinogen Complex.